Patrick John Finn Sells 2,058 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,058 shares of the company’s stock in a transaction that occurred on Wednesday, April 23rd. The shares were sold at an average price of $39.99, for a total value of $82,299.42. Following the sale, the chief operating officer now directly owns 265,460 shares in the company, valued at approximately $10,615,745.40. This represents a 0.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Patrick John Finn also recently made the following trade(s):

• On Wednesday, April 2nd, Patrick John Finn sold 206 shares of Twist Bioscience stock. The stock was sold at an average price of $38.73, for a total transaction of $7,978.38.
• On Monday, February 3rd, Patrick John Finn sold 2,845 shares of Twist Bioscience stock. The shares were sold at an average price of $49.35, for a total value of $140,400.75.

Twist Bioscience Price Performance

Shares of NASDAQ:TWST opened at $40.11 on Friday. The stock has a market cap of $2.39 billion, a price-to-earnings ratio of -11.87 and a beta of 2.34. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. Twist Bioscience Co. has a 12 month low of $30.32 and a 12 month high of $60.90. The stock’s 50 day moving average price is $39.67 and its 200 day moving average price is $44.27.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. The company had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company’s quarterly revenue was up 24.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.75) EPS. Equities research analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. lifted its stake in Twist Bioscience by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company’s stock valued at $269,860,000 after purchasing an additional 189,791 shares during the last quarter. ARK Investment Management LLC boosted its stake in shares of Twist Bioscience by 4.4% during the 4th quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company’s stock worth $260,040,000 after acquiring an additional 237,772 shares in the last quarter. Thrivent Financial for Lutherans grew its holdings in shares of Twist Bioscience by 54.6% in the 4th quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company’s stock worth $69,972,000 after acquiring an additional 532,040 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Twist Bioscience by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 1,374,667 shares of the company’s stock worth $63,895,000 after purchasing an additional 6,908 shares during the period. Finally, First Light Asset Management LLC purchased a new stake in shares of Twist Bioscience during the fourth quarter valued at $56,984,000.

Analyst Ratings Changes

A number of research firms recently issued reports on TWST. JPMorgan Chase & Co. boosted their price objective on Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research report on Tuesday, February 4th. Robert W. Baird boosted their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a report on Tuesday, February 4th. Barclays lowered their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating for the company in a research report on Thursday, April 10th. Scotiabank reissued an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Finally, Guggenheim set a $50.00 price target on shares of Twist Bioscience in a research note on Friday, March 28th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $52.80.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.